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Abstract
Introduction A proliferation-inducing ligand (APRIL) from the
TNF family, owing to its role in the generation and survival of
plasma cells (PCs), is currently targeted for rheumatoid arthritis
(RA) treatment. However, little is known about APRIL expression
in RA lesions, hampering our understanding of the way APRIL
may modulate this autoimmune disease.
Methods We performed immunological staining of human
normal, non-RA and RA synovial tissues with a pair of antibodies
specifically recognizing APRIL-producing cells and secreted
APRIL.
Results We detected significant amounts of secreted APRIL in
normal synovium mostly concentrated around blood vessels and
at the lining layer, but no cells producing APRIL. Meanwhile, we
observed that blood neutrophils constitutively secrete APRIL,
indicating that blood APRIL may diffuse into the synovium via its
fenestrated vessels. Synovium from non-RA and RA patients
retained similarly secreted APRIL, but in this case APRIL-
producing cells, including neutrophils and macrophages, were
present in the tissue. Notably, PCs - when present in RA
synovium - accumulated in areas of APRIL retention, spreading
from blood vessels towards the lining layer.
Conclusions PCs accumulate in synovial zones rich in secreted
APRIL, consistent with a pro-survival role of APRIL for PCs in
RA. The concentration of APRIL by normal synovium indicates
that this tissue may constitute a proper environment for PCs
even before RA onset.
Introduction
A proliferation-inducing ligand (APRIL, TNFSF13) is one of the
latest members cloned from the TNF superfamily [1]. APRIL
modulates late steps of humoral immune responses by induc-
ing immunoglobulin switch [2-5], and by transmitting a survival
signal into plasmablast/plasma cells (PCs) [6-8]. In cancer
patients, APRIL promotes selectively the development of
chronic lymphocytic leukemia [9] and diffuse large B-cell lym-
phoma [10]. This selectivity is consistent with the restricted
expression of APRIL signaling receptors - the transmembrane
activator, calcium modulator and cyclophilin ligand interactor
(TACI, TNFSFR13), and the B-cell maturation antigen (BCMA,
TNFSFR17) - to specific B-cell differentiation stages [11]. In
addition to TACI and BCMA, heparan sulfate proteoglycans
(HSPG) bind APRIL [12,13] and TACI [14].
APRIL is also implicated in autoimmune pathologies, particu-
larly rheumatic diseases [15]. Use of a soluble form of TACI
that antagonizes both APRIL and the closely related B-cell
activation factor from the TNF family (BAFF, TNFSF13B) [16]
ameliorated rheumatoid arthritis (RA) in mouse models [17-
19]. A subsequent phase I clinical trial with soluble TACI in RA
APRIL: A proliferation-inducing ligand; BAFF: B-cell activation factor; BCMA: B-cell maturation antigen; GC: germinal center; HSPG: heparan sulfate 
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patients showed a decrease in levels of rheumatoid factor and
antibodies against citrullinated proteins in treated patients
[20,21], indicating promising perspectives for such a thera-
peutic approach. Expression of BAFF in RA lesions is well
characterized, with a wide expression in B cells, T cells, fibrob-
last-like synoviocytes [22] and monocyte/macrophages [19].
In contrast, APRIL expression appears much more restricted,
since only CD83+ dendritic cells [19] and fibroblast-like syn-
oviocytes [23] have been reported to produce APRIL in RA
lesions.
Ectopic germinal centers (GCs) with PC generation are
present in more than 10% of RA patients [24]. Knowing the
role of APRIL in humoral immunity, we studied APRIL expres-
sion in RA lesions, with particular attention to lesions with
GCs, and compared this expression with normal and non-RA
synovium samples. We performed the present study with a
pair of well-characterized antibodies selectively recognizing
APRIL-producing cells and secreted APRIL in tissues [10].
The pattern of expression for APRIL observed here is consist-
ent with a pro-survival role of APRIL for synovial PCs.
Materials and methods
Patients
Synovial biopsies were obtained from the Geneva School of
Medicine and from the Charité Universitätsmedizin in agree-
ment with local ethics committees and patients' informed con-
sent upon knee arthroscopy of patients with active disease.
Clinical diagnosis was performed for psoriatic arthritis accord-
ing to Moll and Wright [25], and for RA according to the clas-
sification criteria and of the American College of
Rheumatology [26]. The presence of rheumatoid factor of IgM
serotype or IgA isotype defined seropositivity. We defined
GCs by a characteristic histomorphology and the presence of
CD23+ follicular dendritic cells [27].
The patient demography is presented in Table 1. Normal syn-
ovium samples were obtained during autopsies. Non-inflamed
tonsils were obtained from patients who underwent surgery for
snoring problems.
Immunohistochemistry
Immunohistochemistry analyses were performed on formalin-
fixed paraffin-embedded tissues. Polymorphonuclear cells and
peripheral blood mononuclear cells, obtained as previously
described [10], were injected into a fragment of a murine
intestine. The intestine fragment was then processed as a tis-
sue for immunohistochemistry. Stalk-1, Aprily-2 (and its com-
petition with soluble APRIL), Aprily-8, anti-CD138, anti-human
immunoglobulin, anti-elastase and the corresponding second-
ary antibodies have all been previously described [10]. The
anti-CD68 (clone PG-M1, IgG3; Santa Cruz, CA, USA) was
used at 3 μg/ml with anti-IgG3  conjugated to biotin and
streptavidin conjugated to Alexa 488 (Becton Dickinson Bio-
sciences, San Jose, CA, USA). The anti-heparan sulfate 10e4
(Seikagaku Corporation, Tokyo, Japan) was used at 1 μg/ml.
Images were visualized under light or fluorescent microscopy
with Axiophot 1 (Carl Zeiss AG, Berlin, Deutschland), cap-
tured with an axiocam (Carl Zeiss AG) color CCD camera, and
treated on a Pentium III computer with axioVision™ software
(Carl Zeiss AG). The original magnification was 20× unless
stated. In some experiments, 4',6'-diamidino-2-phénylindole
Table 1
Patient demography
Rheumatoid arthritis
Sex 8 males 3 females
Age (years) 43 (30 to 78)
Disease duration (years) 3.8 (1 to 7)
Seropositivity 9
With germinal center 3
Treatment
Nonsteroidal anti-inflammatory drug 4
Methothrexate 3
Methothrexate + prednisolone 3
Lefluonimide + prednisone 1
Non-rheumatoid arthritis
Psoriatic arthritis
Sex 2 males 3 females
Age (years) 53 (45 to 80)
Disease duration (years) 10.3 (5 to 12)
Treatment
Methothrexate 3
Sulfasalazin 2
Lyme
Sex Male
Age (years) 55
Disease duration (years) 3
Treatment
Nonsteroidal anti-inflammatory drug
Gout
Sex Male
Age (years) 65
Disease duration (years) 3
Treatment
Nonsteroidal anti-inflammatory drug
Data presented as n or median (range).Available online http://arthritis-research.com/content/11/5/R144
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staining was included in the merged images. Confocal analy-
ses were performed with a LSM 510 microscope (Carl Zeiss
AG). For quantification of the Aprily-2 signal, images of the lin-
ing layers and blood vessels for RA lesions and for normal syn-
ovium, respectively, were acquired with the 40× objective. An
area of identical size in a zone exhibiting the strongest staining
was selected for each lesion, and was processed using Meta-
Morph Image Analysis software (Molecular Devices, Union
City, CA, USA). Color thresholds were selected in the Hue,
Saturation, Intensity space. Saturation values obtained in the
threshold field were added, logged to a spreadsheet, and
expressed in arbitrary units. Stalk-1 stained cells were numer-
ated in the corresponding area from a serial cut, after image
acquisition with the 40× objective and counting the entire
field, corresponding to a tissue area of 30 mm2.
Flow cytometry
Human umbilical vein endothelial cells (HUVECs) were cul-
tured as described by Bradfield and colleagues [28]. The cells
were harvested from culture dishes with PBS 3 mM ethylene-
diamine tetraacetic acid at 37°C and were washed twice with
PBS. Binding of ACRP30-APRIL in the presence or absence
of heparin was performed as previously described [10]. Bind-
ing was assessed by flow cytometry on a FACSCAN and Cel-
lquest (Becton Dickinson Biosciences).
Results
Presence of secreted APRIL in normal synovium
We first assessed by immunohistochemistry the presence of
APRIL-producing cells and secreted APRIL in normal synovial
tissues. Cells producing APRIL, detected by the Stalk-1 anti-
body, were not present. In rare cases, positive cells were
Figure 1
Concentration of secreted APRIL in normal synovium Concentration of secreted APRIL in normal synovium. (a) Normal synovium was immunostained with control immunoglobulin (cIg) (left panel) and 
Stalk-1 (middle panel). Stalk-1 stained cells are present in blood vessels (lower insert). A serial section of the same synovium was immunostained 
with Aprily-2 (right panel). Insert: Aprily-2 staining in the absence (upper) or presence of recombinant soluble A proliferation-inducing ligand (APRIL) 
(lower). (b) Normal synovium (upper panels, n = 4) and non-inflamed tonsils (lower panels, n = 7) were immunostained with cIg (left panel), Aprily-2 
(middle panel), and anti-heparan sulfate proteoglycans (HSPG) (right panel). Blood vessels from these two organs are shown. Original magnifica-
tion, 100×. (c) Binding of recombinant APRIL on the surface of human umbilical vein endothelial cells was assessed by flow cytometry in the pres-
ence or absence of heparin (hep). ACRP30 was used as a negative control.Arthritis Research & Therapy    Vol 11 No 5    Gabay et al.
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present in blood vessels irrigating the tissue (Figure 1a, insert,
middle panel). Despite the paucity in APRIL-producing cells,
the secreted product, detected by the Aprily-2 antibody, was
significantly present in these samples, bound onto cells from
the lining layer and endothelial cells (Figure 1a, right panel).
We obtained a similar staining with Aprily-8, a second mAb
against secreted APRIL (data not shown). This staining in nor-
mal synovium was specific, since it was abolished by preincu-
bation of the anti-APRIL mAb with soluble APRIL (Figure 1a,
right panel, inserts). Owing to their reactivity against the furin-
processed extracellular domain of APRIL, we cannot exclude
that Aprily-2 and Aprily-8 recognized the hybrid molecule
between TNF-like weak inducer of apoptosis and APRIL,
TWEPRIL [29], and heterotrimers between BAFF and APRIL
[30] in these tissues.
The presence of secreted APRIL on synovial blood vessels
correlated well with their expression of the APRIL-binding part-
ner, HSPG (Figure 1b). We did not observe such accumula-
tion of secreted APRIL in blood vessels irrigating a secondary
lymphoid organ, such as tonsils, despite the fact that tonsil
vessels expressed comparable amounts of HSPG. In an in
vitro staining assay, we confirmed binding of secreted APRIL
at the surface of endothelial cells (Figure 1c). In this experi-
ment, APRIL bound to HSPG since it was inhibited by heparin,
a potent antagonist of APRIL/HSPG interactions [12].
Taken together, these findings indicate that the normal syno-
vial tissue concentrates specifically secreted APRIL.
Blood neutrophils secrete constitutively APRIL
Most proteins in the synovium originate from the blood [31].
This process is due to the fenestration of blood vessels irrigat-
ing this tissue [32]. APRIL concentrated by the synovial tissue
may therefore originate from blood. To test this hypothesis, we
studied APRIL expression in blood.
We have already reported that blood neutrophils express
APRIL mRNA in the steady state [10]. In the present article we
further show that APRIL-producing cells were confined to the
polymorphonuclear cell fraction, since these APRIL-producing
cells were absent from the peripheral blood monoculear cell
fraction. Blood polymorphonuclear cells readily secrete all of
the APRIL they produce, since we observed no staining with
Aprily-2 (Figure 2a). This constitutive secretion of APRIL by
blood polymorphonuclear cells is consistent with the presence
of secreted APRIL over the nanogram per milliliter range
(median, 6.1 ng/ml; range 1 to 12 ng/ml) in sera from healthy
donors (Figure 2b). This result is in accordance with previous
studies [9,33], but is far inferior to the median of 96.7 ng/ml
measured in RA sera with the same ELISA kit [34]. This detec-
tion we observed in normal sera is specific to APRIL, since it
was not observed in xenogeneic murine sera. Secreted APRIL
present in the synovium is therefore most probably diffusing
from the blood, owing to the fenestration of synovial vessels.
APRIL production and retention in inflamed RA 
synovium
We next analyzed inflamed synovial tissues from RA patients
and non-RA patients. APRIL-producing cells were again
present in blood vessels, but the majority was now infiltrating
the synovial tissue or the lining layer in RA lesions (Figure 3a).
The majority of the cells in the vicinity retained secreted APRIL.
We identified APRIL-producing cells infiltrating the tissue as
neutrophils expressing elastase in such inflamed tissues (Fig-
ure 3b). These neutrophils were all brightly stained with Stalk-
1, but a second population - exhibiting a dull Stalk-1 staining
and no expression of elastase - was also present. We identi-
fied these cells as macrophages expressing CD68 (Figure
3c). The intensity of Stalk-1 staining was not the only differ-
ence between APRIL-producing synovial neutrophils and mac-
rophages. Indeed, Aprily-2 stained the Stalk-1dull
macrophages but not the Stalk-1bright neutrophils (Figure 3d).
Co-staining of CD68 with Aprily-2 confirmed that the dull
Aprily-2+ cells were synovial macrophages (Figure 3e). Confo-
cal analysis showed that the overlap between Stalk-1 and
Aprily-2 staining was not complete in the Stalk-1dull cells (Fig-
ure 3f). This indicates that synovial macrophages retained the
secreted APRIL they produced, and/or bound secreted APRIL
from the extracellular medium.
Aprily-2 also stained Stalk-1- cells, indicating that nonproduc-
ing cells also retained secreted APRIL. Stalk-1+ cells were
also present in the lining layer from a minority (3/9 patients) of
RA patients. The lining layer contains fibroblast-like synovio-
cytes, reported by others to produce APRIL when cultured
[23]. The Stalk-1 stained cells in the lining layer, however,
were not fibroblast-like synoviocytes based on morphological
criteria. T cells can also produce APRIL [29], but the T cells
infiltrating RA lesions were not stained by Stalk-1 (data not
shown).
We noticed that APRIL expression was variable among
patients with the same disease entity, but was very similar
when non-RA patients and RA patients were compared. Fig-
ure 4 provides a quantification of secreted APRIL in selected
zones exhibiting the highest retention of APRIL from normal
synovium, non-RA lesions and RA lesions. Secreted APRIL
expression per surface of tissue increased by only 1.4-fold and
1.7-fold upon synovium inflammation in non-RA and RA
patients, respectively, despite the fact that the number of cells
producing APRIL increased by more than fourfold and seven-
fold, respectively. The lesions from patients with Lyme's dis-
ease had the lowest number of APRIL-producing cells and
secreted APRIL. The seronegative RA cases were not differ-
ent from the seropositive cases in this analysis. In these
inflamed lesions, we again observed zones with high concen-
tration of secreted APRIL and a low number of producing cells
in the adjacent area, confirming that the synovium efficiently
retains secreted APRIL.Available online http://arthritis-research.com/content/11/5/R144
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Taken together, inflammatory reactions within synovial tissues
recruit neutrophils and macrophages, insuring high levels of
APRIL production, both in non-RA lesions and RA lesions.
Retention of secreted APRIL per zone was only slightly
increased compared with normal synovium.
Plasma cells in RA lesions accumulate in APRIL-rich 
niches
We next studied PC localization in RA synovial tissues with
ectopic GCs. One should note that such RA lesions did not
show significantly more APRIL expression that non-RA lesions
or RA lesions without GCs (see Figure 4). CD138+ PCs
localized in the periphery of GCs (Figure 5). The GC periph-
ery, however, was a transit area for synovial PCs, since we
observed them mostly concentrated around blood vessels,
forming a full crown in the case of small vessels (insert). When
the density of PCs became high, they were still around blood
vessels but were also extending towards the lining layer. At
high density, PCs were in close contact with CD68 macro-
phages (Figure 5a), in zones of high concentration of secreted
APRIL (Figure 5b). PCs therefore accumulate in APRIL-rich
zones of highly inflamed synovial tissues.
Discussion
In the present study we report a significant expression of
APRIL in the synovium of normal donors, non-RA and RA
patients. Concentration of secreted APRIL per defined area
was only slightly upregulated in non-RA and RA patients com-
pared with normal donors. In contrast, the density of APRIL-
producing cells greatly increased in inflamed synovium.
Recruitment of APRIL-producing cells is therefore not specific
to RA, but the presence of such cells in non-RA lesions is con-
sistent with the detection of secreted APRIL in the synovial
fluid from non-RA patients reported by others [35,36]. Since
neutrophils are the major source of APRIL in these latter
lesions, our study indicates that presence of APRIL is a con-
sequence of the ongoing inflammation in these diseases. In
non-RA lesions, APRIL may be a bystander inflammatory prod-
uct with no specific role in the pathological process, owing to
the current knowledge in APRIL physiology.
Figure 2
Blood neutrophils secrete constitutively APRIL Blood neutrophils secrete constitutively APRIL. (a) Polymorphonuclear cells (PMN) and peripheral blood monoculear cells (PBMC) were embedded 
into mouse intestine and stained with Stalk-1 and Aprily-2. (b) Levels of A proliferation-inducing ligand (APRIL) in serum were determined with an 
ELISA KIT for human APRIL in healthy donors (Hu). To assess the specificity of the detection, mouse xenogeneic sera were tested as negative con-
trol (Mu).Arthritis Research & Therapy    Vol 11 No 5    Gabay et al.
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Figure 3
APRIL production increases in synovium from rheumatoid arthritis patients APRIL production increases in synovium from rheumatoid arthritis patients. (a) Control immunoglobulin (cIg), Stalk-1 and Aprily-2 stainings for a syn-
ovium from a rheumatoid arthritis (RA) patient. Arrow: Stalk-1 stained cell present in the lining layer. (b) Two-color immunofluorescence shows that 
Stalk-1bright cells (green) are elastase+(red) neutrophils. Stalk-1dull cells do not express elastase (arrow). (c) Stalk-1dull cells (green) are macrophages 
expressing CD68 (red). (d) Stalk-1dull cells produce A proliferation-inducing ligand (APRIL) (green) and are positive for secreted APRIL (red) (arrow-
head), while Stalk-1bright cells (arrow) do not. (e) CD68+ macrophages (green) retain secreted APRIL (red). (f) Two-color immunofluorescence and 
confocal analysis shows that Stalk-1 staining (green) is associated with Aprily-2 (red) staining in a single cell, but is not fully colocalized. Original 
magnification, 100×. Pictures representative of 11 RA lesions.Available online http://arthritis-research.com/content/11/5/R144
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Since APRIL plays a major role in the immunoglobulin switch
process and PC survival, one may expect that APRIL promotes
autoimmune reactions associated with production of autoanti-
bodies, such as RA. In the present study we report the pres-
ence of cells producing and secreting APRIL, including
neutrophils and macrophages within RA lesions. Neutrophils
constitute a major source of APRIL in tissues, while macro-
phages generally do not produce this molecule [37]. Synovial
macrophages are therefore different from macrophages in
other tissues. In addition, synovial macrophages are also dif-
ferent from neutrophils in their mode of APRIL production.
They produce less APRIL, and process efficiently the full-
length product - but instead of secreting all of the produced
APRIL, they retain some of it and/or bind secreted APRIL
present in the extracellular medium. In contrast, retention and
binding of secreted APRIL by neutrophils has never been
observed. This is probably due to the lack of HSPG expression
by neutrophils [10], compared with macrophages [38].
We frequently noticed a discrepancy between the concentra-
tion of the secreted APRIL product within the tissues and the
density of APRIL-producing cells. This difference was best
observed in normal synovium. Indeed, in samples from sub-
jects without arthritis, we detected significant levels of
secreted APRIL, covering the lining layer and endothelial cells,
despite the paucity of APRIL-producing cells. This finding indi-
cates that the normal synovial tissue is able to retain substan-
tial amounts of secreted APRIL. Blood vessels irrigating the
synovium are fenestrated, allowing the diffusion of blood pro-
teins, and it is probable that APRIL produced constitutively by
circulating neutrophils diffuses from the blood to accumulate
into the synovial tissue. We previously showed that HSPG
retain APRIL in various tissues [8,10,39,40]. In a healthy syn-
ovium, syndecan-3/glypican-4 and syndecan-2/syndecan-3/
glypican-4 - expressed by the lining layer and endothelial cells,
respectively [41] - are likely to be the proteic carriers of
heparan sulfate chains mediating APRIL retention. The accu-
mulation of APRIL by the synovial vessels is specific to this tis-
sue, since tonsil vessels do not retain secreted APRIL,
consistent with the absence of fenestration for blood vessels
in tonsils.
The study of lesions with ectopic GCs and generation of PCs
led to some valuable observations regarding the role of APRIL
in RA. Indeed, we noticed that PCs migrate from GCs towards
endothelial cells. PC localization around blood vessels in RA
lesions was reported a long time ago [42]. The recent detec-
tion of the PC chemoattractant CXCL-12 on synovial vessels
explained this homing [43]. In the present study, we further
provide evidence that PCs receive a survival signal from these
endothelial cells, given in a trans fashion, similarly to tonsillar
epithelial cells [8]. When PCs accumulate extensively, they
were also in contact with cells from the lining layer and syno-
vial macrophages, both rich in secreted APRIL. The accumula-
tion of APRIL in several synovial cells may therefore explain the
persistence of PCs within the inflamed synovial tissue, as
already proposed [27].
Conclusions
The present study demonstrates that normal synovium and
pathologic synovium both for non-RA and RA patients retain
soluble APRIL, constituting APRIL-rich niches. These niches
are similar to those recently observed in mucosa-associated
lymphoid tissues, wherein plasma cells survive to secrete
locally antibodies against infectious agents. In non-RA lesions,
these niches may not be functional. These APRIL-rich niches
may provide an adequate environment for synovial PCs in RA
lesions, therefore contributing to the generation of pathogenic
autoantibodies. The specific retention of soluble APRIL in a
Figure 4
Quantification of APRIL production and secretion in healthy and rheumatoid arthritis synovium Quantification of APRIL production and secretion in healthy and rheumatoid arthritis synovium. Quantification of the Aprily-2 staining (left y axis) and 
the number of Stalk-1-stained cells (right y axis) for normal synovial tissues (n = 4), for non-rheumatoid arthritis (RA) lesions (n = 7) and for RA 
lesions (n = 11). Arbitrary units are used for Aprily-2 quantification. Number of stalk-1-stained cells shown for an adjacent area of 30 mm2. Mean val-
ues are indicated. *RA lesions with germinal centers and plasma cells. **Seronegative RA lesions. APRIL, A proliferation-inducing ligand.Arthritis Research & Therapy    Vol 11 No 5    Gabay et al.
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normal synovium indicates that this organ offers a favorable
environment for PCs, even before disease onset.
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Figure 5
Synovial plasma cells in rheumatoid arthritis lesions accumulate in zone of secreted APRIL retention Synovial plasma cells in rheumatoid arthritis lesions accumulate in zone of secreted APRIL retention. (a) A rheumatoid arthritis (RA) lesion was 
stained with a control immunoglobulin (cIg) or an anti-CD138. Middle panel: zone with a germinal center (GC) and a low CD138+ plasma cell (PC) 
density; arrows indicate examples of the many blood vessels harboring PC accumulation; Insert, high magnification of PCs accumulating around a 
blood vessel. Right panel: same RA lesion in an area with high CD138+ PC density; arrow indicates example of PCs accumulating around blood ves-
sels. (b) CD138+ plasma cells (green) at high density are in close contacts with CD68+ macrophages (red). (c) Ig+ PCs (green) at high density 
accumulate close to secreted A proliferation-inducing ligand (APRIL) (red). Pictures are representative of three RA lesions with ectopic GC forma-
tion and PC accumulation.Available online http://arthritis-research.com/content/11/5/R144
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